Anthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials
Anthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials
复制标题
DOI：
10.1038/sj.bjc.6605961
复制
发表时间：
2010-11-09
影响因子：
8.8
通讯作者：
Jaeger, E.
中科院分区：
文献类型：
--
作者：
Al-Batran, S-E;Guentner, M.;Jaeger, E.
背景技术背景：本研究的目的是确定蒽环类抗生素再激发使用聚乙二醇脂质体阿霉素（PLD）的活性与转移性乳腺癌（MBC）以前治疗与常规anthracyclines.METHODS：汇总的个人数据从四个前瞻性试验，和汇总分析的主要终点是临床获益率（CBR）。这些研究包括935例患者，其中274人接受了PLD在转移性设置后，以前暴露于传统的蒽环类药物（再激发人群）。既往蒽环类药物治疗用于辅助治疗（14%）或转移性治疗（46%），或两者兼而有之（40%）。PLD再激发的总体CBR为37.2%（95% CI，32.4-42.0）。在单变量分析中，既往化疗暴露较少的患者、未接受过紫杉烷治疗的患者以及东部协作组体能状态良好的患者（0 vs 1 vs 2）的CBR显著较高（53.3 vs 35.5 vs 18.2%; P
BACKGROUND: The aim of this study was to determine the activity of anthracycline rechallenge using pegylated liposomal doxorubicin (PLD) in patients with metastatic breast cancer (MBC) previously treated with conventional anthracyclines.METHODS: Pooled individual data from four prospective trials were used, and the primary end point of the pooled analysis was clinical benefit rate (CBR). The studies comprised 935 patients, of whom 274 had received PLD in the metastatic setting after prior exposure to conventional anthracyclines (rechallenge population).RESULTS: The majority of patients were heavily pretreated. Previous anthracycline therapy was administered in the adjuvant (14%) or metastatic setting (46%), or both (40%). The overall CBR from rechallenge with PLD was 37.2% (95% CI, 32.4-42.0). In univariate analyses, the CBR was significantly higher in patients with less exposure to prior chemotherapy, in taxane-naive patients, and in patients with a favourable Eastern Cooperative Group performance status of 0 vs 1 vs 2 (53.3 vs 35.5 vs 18.2%; P